The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia

Leukemia

Volumn 28, Issue 6, 2014, Pages 1242-1251

  Jacoby, M A ^a   De Jesus Pizarro, R E ^a   Shao, J ^a   Koboldt, D C ^a   Fulton, R S ^a   Zhou, G ^a   Wilson, R K ^a   Walter, M J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA damage; DNA repair; therapy related AML; trisomy 8

Indexed keywords

FLT3 LIGAND; INTERLEUKIN 3; INTERLEUKIN 6; STEM CELL FACTOR; THROMBOPOIETIN; DOUBLE STRANDED DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 8; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; INDEL MUTATION; LYMPHOCYTE; MOUSE; MYELOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; THERAPY RELATED ACUTE MYELOID LEUKEMIA; TRISOMY 8; UPREGULATION; ACUTE LEUKEMIA; DNA REPAIR; DNA STRAND BREAKAGE; GENE SEQUENCE; GENOTYPE; HUMAN TISSUE; LEUKEMOGENESIS; PHENOTYPE; TUMOR CELL;

ANIMALS; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 8; COMET ASSAY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GRANULOCYTE PRECURSOR CELLS; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902074657     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.368     Document Type: Article

References (45)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
2. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16: 2366-2378. (Pubitemid 36067289)
3. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945. (Pubitemid 29516926)
4. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137-2145.
5. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003; 102: 43-52. (Pubitemid 36759634)
6. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-125. (Pubitemid 38159447)
7. Li FP, Fraumeni Jr JF. Prospective study of a family cancer syndrome. JAMA 1982; 247: 2692-2694. (Pubitemid 12105070)
8. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20: 4621-4628. (Pubitemid 32762434)
9. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genet 2013; 45: 242-252.
10. Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008; 49: 204-217. (Pubitemid 351193913)
11. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res: 2004; 10: 2675-2680. (Pubitemid 38509141)
12. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013; 98: 908-912.
13. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240-248. (Pubitemid 351250527)
14. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296-4303. (Pubitemid 26399177)
15. Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: An M-FISH study. Genes Chromosomes Cancer 2005; 42: 358-371. (Pubitemid 40271279)
16. Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S et al. Identification of a novel TP53 cancer susceptibility mutation through wholegenome sequencing of a patient with therapy-related AML. JAMA 2011; 305: 1568-1576.
17. Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv Genet 2013; 82: 1-45.
18. Ramsingh G, Jacoby MA, Shao J, De Jesus Pizzaro RE, Shen D, Trissal M et al. Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood 2013; 122: E44-e51.
19. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 2009; 106: 12950-12955.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
21. Zeller KI, Jegga AG, Aronow BJ, ODonnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: Identification of direct genomic targets. Genome Biol 2003; 4: R69.
22. Luo H, Li Q, ONeal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-Associated antiapoptotic mutations. Blood 2005; 106: 2452-2461. (Pubitemid 41510820)
23. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146: 905-916.
24. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S et al. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8: 957-967.
25. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59-71.
26. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
27. Fairbairn DW, Olive PL, ONeill KL. The comet assay: A comprehensive review. Mutation research 1995; 339(1): 37-59.
28. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol Cell 2002; 9: 1031-1044. (Pubitemid 34626672)
29. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective doublestrand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA. 2003; 100: 9974-9979. (Pubitemid 37087053)
30. Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 2006; 66: 6598-6605. (Pubitemid 44085615)
31. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med 2013; 368: 2059-2074.
32. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med 2010; 207: 2581-2594.
33. Li Z, Owonikoko TK, Sun SY, Ramalingam SS, Doetsch PW, Xiao ZQ et al. c-Myc suppression of DNA double-strand break repair. Neoplasia 2012; 14: 1190-1202.
34. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA et al. Genomic instability in mice lacking histone H2AX. Science 2002; 296: 922-927. (Pubitemid 34464900)
35. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 2003; 114: 371-383. (Pubitemid 36962935)
36. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M et al. Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003; 114: 359-370. (Pubitemid 36962934)
37. Riches LC, Lynch AM, Gooderham NJ. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 2008; 23: 331-339.
38. Mirzayans R, Severin D, Murray D. Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: Implications for evaluation of clinical radiosensitivity. Int J Rad Oncol, Biol, Phys 2006; 66: 1498-1505.
39. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114-2121.
40. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004; 64: 7144-7149. (Pubitemid 39331029)
41. Zheng H, Chen L, Pledger WJ, Fang J, Chen J. p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression. Oncogene 2014; 33: 734-744.
42. Moon SH, Nguyen TA, Darlington Y, Lu X, Donehower LA. Dephosphorylation of gamma-H2AX by WIP1: An important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle 2010; 9: 2092-2096.
43. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109: 2399-2405. (Pubitemid 46425880)
44. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
45. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.